Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase I/II Trial of CHOEP Chemotherapy Plus Lenalidomide as Front Line Therapy for Patients With Stage II, III and IV Peripheral T-Cell Non-Hodgkin's Lymphoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT02561273
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:39:24.923704+00:00
Published At
2021-06-18T00:00:00+00:00
Record Updated At
2023-12-13
Results Posted At
2021-06-18
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Anaplastic Large Cell Lymphoma, ALK-Negative", "Anaplastic Large Cell Lymphoma, ALK-Positive", "Hepatosplenic T-Cell Lymphoma", "Peripheral T-Cell Lymphoma, Not Otherwise Specified", "Stage II Angioimmunoblastic T-cell Lymphoma", "Stage II Enteropathy-Associated T-Cell Lymphoma", "Stage III Angioimmunoblastic T-cell Lymphoma", "Stage III Enteropathy-Associated T-Cell Lymphoma", "Stage IV Angioimmunoblastic T-cell Lymphoma", "Stage IV Enteropathy-Associated T-Cell Lymphoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2023-12-13"
protocolSection.identificationModule.nctId
"NCT02561273"
protocolSection.identificationModule.officialTitle
"A Phase I/II Trial of CHOEP Chemotherapy Plus Lenalidomide as Front Line Therapy for Patients With Stage II, III and IV Peripheral T-Cell Non-Hodgkin\u0027s Lymphoma"
protocolSection.statusModule.overallStatus
"COMPLETED"
protocolSection.designModule.phases
["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
"2021-06-18"

Study condition terms

  • Anaplastic Large Cell Lymphoma, ALK-Negative (protocolSection.conditionsModule.conditions)
  • Anaplastic Large Cell Lymphoma, ALK-Positive (protocolSection.conditionsModule.conditions)
  • Hepatosplenic T-Cell Lymphoma (protocolSection.conditionsModule.conditions)
  • Peripheral T-Cell Lymphoma, Not Otherwise Specified (protocolSection.conditionsModule.conditions)
  • Stage II Angioimmunoblastic T-cell Lymphoma (protocolSection.conditionsModule.conditions)
  • Stage II Enteropathy-Associated T-Cell Lymphoma (protocolSection.conditionsModule.conditions)
  • Stage III Angioimmunoblastic T-cell Lymphoma (protocolSection.conditionsModule.conditions)
  • Stage III Enteropathy-Associated T-Cell Lymphoma (protocolSection.conditionsModule.conditions)
  • Stage IV Angioimmunoblastic T-cell Lymphoma (protocolSection.conditionsModule.conditions)
  • Stage IV Enteropathy-Associated T-Cell Lymphoma (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.